Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study.

Kévin BigautLaurent KremerThibaut FabacherLivia LanotteMarie-Celine FleuryNicolas Collongues Jérôme de Sèze

Published in: Neurology(R) neuroimmunology & neuroinflammation (2021)

This study provides Class IV evidence that patients treated with fingolimod or anti-CD20 monoclonal antibodies for MS have a lower humoral response after COVID-19 compared with patients without DMTs or with another DMTs.

Keyphrases

multiple sclerosis
sars cov
end stage renal disease
coronavirus disease
ejection fraction
newly diagnosed
immune response
mass spectrometry
white matter
respiratory syndrome coronavirus
peritoneal dialysis